• Uncovering the rationale for “hot” PARP inhibitors to address resistance seen with conventional agents

• Examining resistance mechanisms and the role of biomarkers like PET imaging in guiding treatment

• Outlining combination strategies to boost efficacy while managing toxicity challenges